Pacira BioSciences (PCRX) has advanced PCRX-201, its osteoarthritis gene therapy candidate, to a scalable U.S. commercial manufacturing process and has begun enrolling patients in Part B of the Phase 2 ASCEND study.

The latest PCRX-201 update comes as Pacira BioSciences trades at US$26.92, with a 30 day share price return of 6.03% and a 90 day share price return of 13.63%. Over five years, the total shareholder return has declined 52.07%, although the 1 year total shareholder return of 19.43% points to improving momentum.

If you are looking beyond Pacira BioSciences in the same broad healthcare space, this could be a useful moment to scan for other opportunities across 41 healthcare AI stocks

With Pacira BioSciences shares up over the past year yet still well below their five year level, the key consideration is whether that reset already offers a fair entry, or whether waiting for a better price still makes more sense as the next step.

Most Popular Narrative: 29.2% Undervalued

At a last close of $26.92 versus a narrative fair value of $38.00, the current Pacira BioSciences share price sits well below that implied estimate, which puts more focus on the assumptions behind that gap.

Pacira's first-mover advantage and expanded clinical pipeline including disease-modifying therapies like PCRX-201, validated by long-term, real-world outcomes registries and breakthrough designations, position it to capitalize on sustained, multi-decade growth in global surgical volumes and opioid-sparing pain management, supporting stepwise expansion in addressable markets and top-line growth far above current market assumptions.

Investors may want to consider what kind of revenue trajectory and margin profile would need to sit behind that view. The narrative leans on compounding earnings, expanding profitability, and a future valuation multiple that looks very different to today.

Result: Fair Value of $38 (UNDERVALUED)

However, there are still real risks to watch, including potential pricing pressure on Pacira BioSciences core products, as well as any future generic or biosimilar competition around EXPAREL.

Next Steps

With sentiment on Pacira BioSciences split between opportunity and caution, consider reviewing the full picture yourself, including the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Pacira BioSciences?

If you are serious about building a stronger portfolio, do not stop with Pacira BioSciences. Use the Simply Wall Street Screener to compare, filter, and pressure test other opportunities.

• Target steady income by reviewing companies that qualify as 7 dividend fortresses and see which ones fit your goals.
• Hunt for potential value candidates using the 53 high quality undervalued stocks to spot stocks where fundamentals and price may be out of sync.
• Prioritise resilience by checking the 82 resilient stocks with low risk scores and focus on businesses with more robust risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.